Scout Bio is focused on delivering a pipeline of one-time adeno-associated viral (AAV) gene therapies for major chronic pet health conditions. Its therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Lead product candidates target diabetes, feline pain associated with osteoarthritis, and anemia associated with chronic kidney disease (CKD), and the company is researching additional indications. Scout Bio reported meaningful clinical data in patients with CKD-associated anemia, indicating AAV gene therapy can be efficacious in client-owned animals with chronic diseases. The company has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program. It is a private company headquartered in Philadelphia, Pennsylvania. Proceeds from a recently closed financing will support advancing the clinical development of its programs and platform over the next twelve months. Scout Bio is focused on delivering one-time therapeutics for major chronic pet health conditions using adeno-associated viral (AAV) vector technology. The company’s approach is intended to induce long-term expression of therapeutic proteins in pet patients from a single intramuscular injection. Scout is advancing programs across chronic kidney disease, chronic pain, and atopic dermatitis, with its lead candidate designed to deliver long-term feline erythropoietin (EPO) for cats with anemia associated with chronic kidney disease. The lead program has demonstrated statistically significant increases in red blood cell counts in cats for months after a single injection and has entered a clinical pilot field study. A proprietary survey of 424 veterinarians indicated over 90% would use a product with Scout’s target profile over other treatments. Scout holds an exclusive AAV research and development collaboration and license with the University of Pennsylvania’s Gene Therapy Program and will use recent financing to advance its pipeline and expand clinical and other operations; the company is headquartered in Philadelphia, Pennsylvania.

Total raised

$53M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2021